Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.4.21.5 (thrombin)
33,306 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human platelets generate diglyceride within 5 s of exposure to thrombin. Production of diglyceride is transient. 15 s after the addition of thrombin, the levels of diglyceride have increased up to 30-fold, but decrease thereafter. Prior incubation of platelets with 2 mM dibutyryl cyclic AMP prevents both the generation of diglyceride and the secretion of serotonin. Acetylsalicylic acid (100 microgram/ml), which completely inhibits prostaglandin endoperoxide synthesis, does not block diglyceride production and serotonin secretion induced by thrombin. Based on studies examining the incorporation of [3H]arachidonic acid into diglyceride of prelabeled platelets exposed to thrombin, it is concluded that neither phosphatidic acid nor triglyceride is the source of the diglyceride. Phosphatidylinositol appears to be the most likely source, both because its loss of radiolabel is sizable and rapid enough to account for the appearance of radiolabel in diglyceride, and because a phosphatidylinositol-specific phosphodiesterase, described in this report, exists in platelets. The phosphatidylinositol-phosphodiesterase, which produces diglyceride and inositol phosphate, requires Ca+2 and shows optimal activity at pH 7. The enzyme does not act upon phosphatidylcholine, phosphatidylethanolamine, or phosphatidylserine.
...
PMID:Production of diglyceride from phosphatidylinositol in activated human platelets. 22 Feb 79

We provide evidence that the mechanism for arachidonate release from stimulated human platelets involves two enzymes: a phosphatidylinositol-specific phospholipase C (EC 3.1.4.10) and a diglyceride lipase. After incubation of platelets with thrombin for 15 seconds, 1.2 nmol of 1-stearoyl-2-arachidonoyl diglyceride per 10(9) platelets, was isolated. Arachidonate was released from this substrate by the action of diglyceride lipase located in the particulate fraction of platelets. The enzyme has a pH optimum of 7.0, is stimulated by calcium ions and reduced glutathione, and liberates 31 nmol of fatty acid per min per mg of platelet particulate protein. The diglyceride lipase has sufficient activity to account for the 5-10 nmol of arachidonate released per 10(9) platelets upon thrombin stimulation. That only arachidonate is released upon thrombin stimulation may be explained by the fact that the diglyceride substrate in platelets contains only arachidonate in the 2 position. The lipase activity found in platelet membranes can also hydrolyze the 1-position fatty acid. Stearate is not released when intact platelets are stimulated with thrombin, and the fate of this fatty acid remains to be elucidated.
...
PMID:Diglyceride lipase: a pathway for arachidonate release from human platelets. 29 Sep 99

The urokinase-type plasminogen activator receptor (u-PAR) was demonstrated on cultured smooth muscle cells (SMCs) of bovine aorta. Binding of 125I-urokinase-type plasminogen activator (u-PA) was concentration dependent and saturable within 45-60 minutes. A similar concentration and time dependence was found in functional plasminogen activation studies. Human two-chain high-molecular-weight u-PA and its proenzyme (pro-u-PA) bound specifically with identical affinity (Kd). Activation of pro-u-PA was strongly accelerated on binding to SMCs and occurred only in the presence of plasminogen on the cell surface. A 100-fold molar excess of unlabeled high-molecular-weight u-PA effectively blocked binding of the radiolabeled ligands; tissue-type plasminogen activator, plasminogen, low-molecular-weight u-PA, and unrelated proteins did not. 125I-u-PA binding was abolished by a monoclonal antibody against the specific u-PA sequence responsible for u-PAR binding. Binding of u-PA sharply decreased on SMC exposure to phosphatidylinositol-specific phospholipase C, confirming the glycan phospholipid cell anchorage of u-PAR. Bovine and human alpha-thrombin (240 nM) increased the binding of 125I-u-PA fivefold, translating into an increase in the number of sites per cell from about 10(5) to 5 x 10(5) without significant change in the Kd (1.29 +/- 0.39 nM). Active site blockade of thrombin by D-Phe-Pro-Arg-chloromethyl ketone resulted in the total loss of stimulatory activity, as did the use of the inactive active site thrombin mutant, S205A. Hirugen (100 microM), which blocks the anion-binding exosite of thrombin, blocked u-PAR stimulating activity. Thus, both the catalytic activity and integrity of the exosite are important for thrombin's stimulatory activity. Other SMC mitogens (epidermal growth factor, transforming growth factor-beta 1, basic fibroblast growth factor, platelet-derived growth factor, and phorbol 12-myristate 13-acetate) increased u-PAR expression on SMCs six- to 20-fold while concomitantly increasing Kd four- to 10-fold. In all cases the induction of u-PAR was dependent on de novo protein synthesis. These observations assign a possible role for thrombin and other mitogens in u-PAR regulation, thereby influencing the pericellular proteolysis that is important in SMC migration and atheromatous plaque development.
...
PMID:Regulation of the urokinase-type plasminogen activator receptor on vascular smooth muscle cells is under the control of thrombin and other mitogens. 132 97

In a previous paper (Rath, H. M., Doyle, G. A. R., and Silbert, D. F. (1989) J. Biol. Chem. 264, 13387-13390), we reported a selection for the isolation of Chinese hamster lung fibroblasts (CCL39) defective in thrombin-induced mitogenesis. One mutant, D1-6b, had decreased production of inositol phosphates when challenged with activators of phosphatidylinositol turnover and extracts of this mutant showed a marked decrease in phospholipase C (PLC) activity toward phosphatidylinositol. In the current studies, the PLC activities of wild type CCL39 and D1-6b cytosolic extracts are further characterized. Wild type cytosol had at least two phosphatidylinositol-specific PLC isoenzymes, which could be separated by anion exchange chromatography and behaved differently in thermal inactivation studies. Since gel filtration of PLC activity in wild type extracts gave Mr values similar to that of previously characterized PLCs (140,000-200,000), immunoblots with antibodies to bovine brain isoenzymes were used to show that the PLC activities obtained by anion exchange chromatography were PLC-delta and PLC-gamma. Immunoblots with mutant D1-6b cytosol confirmed the presence of the PLC-gamma but showed no detectable PLC-delta. This activity in the mutant extracts eluted at the same conductivity on anion exchange columns and had the same kinetics of thermal inactivation as the PLC-gamma found in the wild type extracts. PLC-gamma from mutant extracts was active in assays containing phospholipid detergent mixed micelles but not in assays utilizing phospholipid vesicles, in sharp contrast to PLC-gamma from CCL39 extracts, which was active under either condition. Thus, the phosphatidylinositol-specific phospholipase C activity of mutant D1-6b is diminished both by the loss of PLC-delta and by the compromised behavior of PLC-gamma.
...
PMID:Characterization of phosphatidylinositol-specific phospholipase C defects associated with thrombin-induced mitogenesis. 230 41

Platelet aggregation stimulated by thrombin, arachidonic acid or lysophosphatidic acid is associated with rapid phosphorylation of two platelet proteins, myosin light chain and a 47 kDa protein. The polyamine, spermine, inhibited platelet aggregation stimulated by all three agents. Spermine inhibited thrombin-stimulated phosphorylation of myosin light chain and the 47 kDa proteins as well as thrombin-induced production of the inositol phosphates and phosphatidic acid. In contrast, spermine did not inhibit phosphorylation of either protein or the formation of inositol phosphates and phosphatidic acid in response to arachidonic acid or lysophosphatidic acid. Although spermine has been demonstrated to inhibit both phosphatidylinositol-specific phospholipase C and calcium-dependent protein kinases in cell free systems, these results suggest that, in the intact platelet, spermine does not directly inhibit these enzymes. Inhibition of aggregation stimulated by arachidonic acid and lysophosphatidic acid is secondary to interference with platelet-platelet interaction but not with platelet activation. In contrast, spermine inhibits thrombin-induced platelet activation. This thrombin-specific inhibition may be related to interference with the binding of thrombin to its receptor or to its catalytic substrate on the cell surface.
...
PMID:Differential effects of spermine on aggregation, inositol phosphate formation and protein phosphorylation in human platelets in response to thrombin, arachidonic acid and lysophosphatidic acid. 309 Oct 78

The importance of alpha-thrombin in the clotting cascade is well-known, but it is also a potent mitogen. Like many other mitogens, thrombin causes receptor-mediated activation of a phosphatidylinositol-specific phospholipase C (PLC), leading to the release of diacylglycerol and the subsequent activation of protein kinase C (refs 3-6). Protein kinase C is probably important in cell proliferation, as activation of this enzyme by phorbol esters promotes growth in many systems. Some growth factors have tyrosine kinase activity and function without activation of PLC or protein kinase C. In this report we show that alpha-thrombin retains its mitogenicity in vascular smooth muscle cells depleted of protein kinase C. Phorbol-12-myristate-13-acetate (PMA) is found to be a potent growth inhibitor when added to vascular smooth muscle cells with alpha-thrombin. Moreover, growth inhibition is maximal when protein kinase C is activated 4 hours after exposure to thrombin, long after the completion of 'early events' induced by thrombin. Thus, PMA probes an event late in the G1 phase of the cell cycle or at the G1-S transition.
...
PMID:Growth inhibition by protein kinase C late in mitogenesis. 367 Mar 89

Concentrations (1 to 20 microM) of 1-oleoyl-lysophosphatidic acid which alone do not affect platelet metabolism of arachidonic acid, do augment the effects of suboptimal concentrations of thrombin on the formation of [14C]phosphatidic acid and the production of [14C]arachidonate metabolites from platelets prelabeled with [14C]arachidonate. The effect on [14C]phosphatidate occurs with concentrations of thrombin (0.1 unit/ml) which are lower than those (0.2 unit/ml) needed to observe the effects on [14C]arachidonate metabolites. The effect of 1-oleoyl-lysophosphatidic acid (10 microM) plus thrombin (0.2 unit/ml) on the formation of phosphatidic acid temporally precedes the production of arachidonate metabolites consistent with a sequential activation of phosphatidylinositol-specific phospholipase C and phospholipase A2 activities. Preincubation of platelets with (32P)orthophosphate shows that the phosphatidic acid formed by 1-oleoyl-lysophosphatidic acid (10 microM) plus thrombin (0.2 unit/ml) is derived from phosphatidylinositol. The Ca2+-ionophoretic properties of lysophosphatidic acid might explain the accumulation of phosphatidic acid since Ca2+ prevents the conversion of phosphatidic acid to phosphatidylinositol. That effect of lysophosphatidic acid is inhibited by prostacyclin, possibly through a cyclic-AMP-mediated effect on calcium homeostasis.
...
PMID:Lysophosphatidic acid potentiates the thrombin-induced production of arachidonate metabolites in platelets. 679 96

In stimulated platelets phosphatidylinositol is degraded by a phosphatidylinositol-specific phospholipase C to 1,2-diacylglycerol which is then phosphorylated to phosphatidic acid. Thrombin stimulation of horse and human platelets prelabeled with [32P]orthophosphate induces the formation of [32P]lysophosphatidylinositol, suggesting that phosphatidylinositol is also degraded by a phospholipase of A type activity. Stimulation of platelets prelabeled with 32P or with 32P plus [3H]inositol produces a lysophosphatidylinositol which has a 32P-specific activity and a 3H/32P ratio which has a 32P-specific activity and a 3H/32P ratio identical with those of phosphatidylinositol. These results suggest that the lysophosphatidylinositol derives from phosphatidylinositol. Thrombin stimulation of platelets double label with 32P and [3H]arachidonate induces loss of [3H]arachidonate from phosphatidylinositol and formation of [32P]lysophosphatidylinositol, suggesting the involvement of a phospholipase A2 activity. Ionophore A23187 also induces the formation of lysophosphatidylinositol in horse and human platelets. With either stimulus, [32P]lysophosphatidylinositol appears within seconds after stimulation and parallels the loss of [3H]arachidonic acid from phosphatidylinositol. The lysophosphatidylinositol produced by thrombin or by ionophore A23187 represents 40% of the degraded phosphatidylinositol as assessed by lipid phosphorus. Quinacrine, which inhibits the liberation of arachidonic acid from phospholipids, also blocks the formation of lysophosphatidylinositol. The results presented here indicate that phosphatidylinositol is degraded by both phospholipases, C and A2, in stimulated platelets.
...
PMID:Formation of lysophosphatidylinositol in platelets stimulated with thrombin or ionophore A23187. 680 48

Stimulation of platelets with ionophore A23187 or thrombin indicates the existence of three distinct metabolic fractions of phosphatidylinositol. Two of those pools of phosphatidylinositol are degraded by phosphatidylinositol-specific phospholipase C and the third one by a phospholipase A2 activity. Low concentrations of ionophore A23187 (100 nM) or thrombin (0.25 units/ml) induce the degradation by phospholipase C of a minor fraction of phosphatidylinositol which is involved in the phosphatidylinositol cycle. In addition, thrombin, but not ionophore A23187, leads to the degradation by phospholipase C of a larger fraction of phosphatidylinositol and the subsequent accumulation of phosphatidic acid. A third fraction of phosphatidylinositol, sensitive to thrombin (0.5-2 units/ml) or ionophore A23187 (0.5-2 microM), can be degraded by phospholipase A2 to lysophosphatidylinositol with the concomitant liberation of arachidonic acid. Degradation of phosphatidylinositol by the phospholipase C pathway precedes that of the phospholipase A2 pathway. The results also suggest that the phosphatidylinositol cycle is sensitive to a small rise in cytosolic Ca2+ concentration. A further mobilization of cytosolic Ca2+ interrupts the phosphatidylinositol cycle by inhibiting conversion of phosphatidic acid to phosphatidylinositol and also activates phospholipases of the A2 type.
...
PMID:Evidence for multiple metabolic pools of phosphatidylinositol in stimulated platelets. 681 89

When platelets are stimulated by thrombin, a phosphatidylinositol-specific phospholipase C produces a transient rise in 1,2-diacylglycerol. We have now characterized the hydrolysis of diacylglycerol by platelet membranes using doubly isotopically labeled substrates of defined fatty acid composition. We find that the fatty acid at sn-1 is hydrolyzed faster than that at sn-2 thereby producing a 2-monoacylglycerol intermediate. If hydrolysis had occurred at either position randomly, 1-monoacylglycerol would also be produced. That none was detected indicates that either the sn-1 fatty acid must be cleaved first or that 1-monoacylglycerol is hydrolyzed by monoacylglycerol lipase much faster than 2-monoacylglyceol. The latter possibility was excluded by the finding that 1-monoacylglycerol and 2-monoacylglycerol are hydrolyzed at equal rates by platelet membranes. The diacylglycerol lipase cleaves diacylglycerols with sn-1 palmitate as rapidly as those with sn-1 stearate. Arachidonate at sn-2 is cleaved twice as fast as sn-2 oleate by monoacylglycerol lipase. The two activities probably represent discrete enzymes since monoacylglycerol lipase activity can be separated from diacylglycerol lipase by fractionation on DEAE-Sepharose, although both are contained in the membrane fraction of platelets. That the sequential breakdown of 1,2-diacylglycerol also occurs in intact platelets is indicated by our finding of a transient rise in arachidonoyl-monoacylglycerol in thrombin-stimulated platelets. This provides further evidence for a role of the phospholipase C-diacylglycerol lipase pathway in the release of arachidonic acid.
...
PMID:Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. 682 11


1 2 Next >>

---